BioTelemetry to pay $44.8M over India testing false claims
Medical technology company BioTelemetry and its heart rate monitoring subsidiary CardioNet agreed to pay more than $44.8 million to settle allegations they violated U.S. federal health laws by improperly billing Medicare and other federal programs for heart monitoring and cardiac test analyses performed by a company in India.
Federal law requires services for patients of federal health programs, like Medicare, be provided within the United States to be reimbursed.
The trouble began for BioTelemetry in 2013, when it contracted with a group in India to conduct Holter-associated monitoring and interpret the results. The Holter heart monitor is designed to detect faulty and dangerous heart rhythms related to heart attacks and poor heart function.